NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/vnda .
The investigation concerns whether Vanda and certain of its officers and/or directors have violated federal securities laws.
On February 11, 2019, Aurelius Value reported about on a whistleblower lawsuit alleging that, “Vanda has engaged in a series of fraudulent schemes, some personally orchestrated by [its CEO], to defraud government payors.” The lawsuit claims that “illegal off-label promotion of both of Vanda’s drugs, Vanda’s participation in a fraud involving doctors writing hundreds of ‘fake prescriptions’ and pocketing cash using Vanda-issued copay cards, falsified documents in internal systems, and resignations of senior executives who refused to participate in illegal activity.” Following this news, Vanda stock dropped during intra-day trading on February 11, 2019.
If you are aware of any facts relating to this investigation, or purchased Vanda shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/vnda . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com
